The single variable new antigen receptor domain antibody fragments (V NARs) derived from shark immunoglobulin new antigen receptor antibodies (IgNARs) represent some of the smallest known immunoglobulin-based protein scaffolds. As single domains, they demonstrate favorable size and cryptic epitope recognition properties, making them attractive in diagnosis and therapy of numerous disease states. Here, we examine the stability of V NAR domains with a focus on a family of V NARs specific for apical membrane antigen 1 (AMA-1) from Plasmodium falciparum. The V NARs are compared to traditional monoclonal antibodies (mAbs) in liquid, lyophilized and immobilized nitrocellulose formats. When maintained in various formats at 45 °C, V NARs have improved stability compared to mAbs for periods of up to four weeks. Using circular dichroism spectroscopy we demonstrate that V NAR domains are able to refold following heating to 80 °C. We also demonstrate that V NAR domains are stable during incubation under potential in vivo conditions such as stomach acid, but not to the protease rich environment of murine stomach scrapings. Taken together, our results demonstrate the suitability of shark V NAR domains for various diagnostic platforms and related applications.
Roux, K.H.; Greenberg, A.S.; Greene, L.; Strelets, L.; Avila, D.; McKinney, E.C.; Flajnik, M.F. Structural analysis of the nurse shark (new) antigen receptor (nar): Molecular convergence of nar and unusual mammalian immunoglobulins. Proc. Natl. Acad. Sci. USA 1998, 95, 11804–11809.
[3]
Streltsov, V.A.; Varghese, J.N.; Carmichael, J.A.; Irving, R.A.; Hudson, P.J.; Nuttall, S.D. Structural evidence for evolution of shark ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc. Natl. Acad. Sci. USA 2004, 101, 12444–12449.
[4]
Stanfield, R.L.; Dooley, H.; Flajnik, M.F.; Wilson, I.A. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 2004, 305, 1770–1773, doi:10.1126/science.1101148.
[5]
Nuttall, S.D.; Humberstone, K.S.; Krishnan, U.V.; Carmichael, J.A.; Doughty, L.; Hattarki, M.; Coley, A.M.; Casey, J.L.; Anders, R.F.; Foley, M.; et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA-1. Proteins 2004, 55, 187–197, doi:10.1002/prot.20005.
[6]
Kopsidas, G.; Roberts, A.S.; Coia, G.; Streltsov, V.A.; Nuttall, S.D. In vitro improvement of a shark IgNAR antibody by Qβ replicase mutation and ribosome display mimics in vivo affinity maturation. Immunol. Lett. 2006, 107, 163–168, doi:10.1016/j.imlet.2006.09.004.
Coley, A.M.; Campanale, N.V.; Casey, J.L.; Hodder, A.N.; Crewther, P.E.; Anders, R.F.; Tilley, L.M.; Foley, M. Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA-1 by combined phage display of fragments and random peptides. Protein Eng. 2001, 14, 691–698, doi:10.1093/protein/14.9.691.
[11]
Bell, D.; Wongsrichanalai, C.; Barnwell, J.W. Ensuring quality and access for malaria diagnosis: How can it be achieved? Nat. Rev. Microbiol. 2006, 4, S7–S20.
[12]
Chiodini, P.L.; Bowers, K.; Jorgensen, P.; Barnwell, J.W.; Grady, K.K.; Luchavez, J.; Moody, A.H.; Cenizal, A.; Bell, D. The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. Trans. R. Soc. Trop. Med. Hyg. 2007, 101, 331–337, doi:10.1016/j.trstmh.2006.09.007.
[13]
Ashley, E.A.; Touabi, M.; Ahrer, M.; Hutagalung, R.; Htun, K.; Luchavez, J.; Dureza, C.; Proux, S.; Leimanis, M.; Lwin, M.M.; et al. Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria. Malar. J. 2009, 8, 241, doi:10.1186/1475-2875-8-241.
[14]
Greenfield, N.J. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 2006, 1, 2876–2890, doi:10.1038/nprot.2006.202.
[15]
Dudgeon, K.; Rouet, R.; Kokmeijer, I.; Schofield, P.; Stolp, J.; Langley, D.; Stock, D.; Christ, D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc. Natl. Acad. Sci. USA 2012, 109, 10879–10884.
Hussack, G.; Arbabi-Ghahroudi, M.; van Faassen, H.; Songer, J.G.; Ng, K.K.; MacKenzie, R.; Tanha, J. Neutralization of Clostridium difficile toxin a with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 2011, 286, 8961–8976.
[18]
Urdea, M.; Penny, L.A.; Olmsted, S.S.; Giovanni, M.Y.; Kaspar, P.; Shepherd, A.; Wilson, P.; Dahl, C.A.; Buchsbaum, S.; Moeller, G.; et al. Requirements for high impact diagnostics in the developing world. Nature 2006, 444, 73–79.
[19]
Romer, T.; Leonhardt, H.; Rothbauer, U. Engineering antibodies and proteins for molecular in vivo imaging. Curr. Opin. Biotechnol. 2011, 22, 882–887, doi:10.1016/j.copbio.2011.06.007.
Olichon, A.; Schweizer, D.; Muyldermans, S.; de Marco, A. Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. BMC Biotechnol. 2007, 7, 7.
[22]
Muller, R.M.; Saunders, K.; Grace, C.; Jin, M.; Piche-Nicholas, N.; Steven, J.; O'Dwyer, R.; Wu, L.; Khetemenee, L.; Vugmeyster, Y.; et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. mAbs 2012, 4, 673–685, doi:10.4161/mabs.22242.
[23]
Fennell, B.J.; Darmanin-Sheehan, A.; Hufton, S.E.; Calabro, V.; Wu, L.; Muller, M.R.; Cao, W.; Gill, D.; Cunningham, O.; Finlay, W.J. Dissection of the IgNAR V domain: Molecular scanning and orthologue database mining define novel ignar hallmarks and affinity maturation mechanisms. J. Mol. Biol. 2010, 400, 155–170, doi:10.1016/j.jmb.2010.04.061.
[24]
Nuttall, S.D.; Krishnan, U.V.; Doughty, L.; Pearson, K.; Ryan, M.T.; Hoogenraad, N.J.; Hattarki, M.; Carmichael, J.A.; Irving, R.A.; Hudson, P.J. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor tom70. Eur. J. Biochem. 2003, 270, 3543–3554, doi:10.1046/j.1432-1033.2003.03737.x.
[25]
Hodder, A.N.; Crewther, P.E.; Anders, R.F. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 2001, 69, 3286–3294, doi:10.1128/IAI.69.5.3286-3294.2001.
[26]
Coia, G.; Ayres, A.; Lilley, G.G.; Hudson, P.J.; Irving, R.A. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene 1997, 201, 203–209, doi:10.1016/S0378-1119(97)00452-6.
[27]
Nuttall, S.D.; Krishnan, U.V.; Doughty, L.; Nathanielsz, A.; Ally, N.; Pike, R.N.; Hudson, P.J.; Kortt, A.A.; Irving, R.A. A naturally occurring NAR variable domain binds the Kgp protease from Porphyromonas gingivalis. FEBS Lett. 2002, 516, 80–86, doi:10.1016/S0014-5793(02)02506-1.
[28]
Nuttall, S.D.; Rousch, M.J.; Irving, R.A.; Hufton, S.E.; Hoogenboom, H.R.; Hudson, P.J. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides. Proteins 1999, 36, 217–227, doi:10.1002/(SICI)1097-0134(19990801)36:2<217::AID-PROT7>3.0.CO;2-X.
[29]
Minsky, A.; Summers, R.G.; Knowles, J.R. Secretion of beta-lactamase into the periplasm of Escherichia coli: Evidence for a distinct release step associated with a conformational change. Proc. Natl. Acad. Sci. USA 1986, 83, 4180–4184, doi:10.1073/pnas.83.12.4180.
[30]
Gupta, A.; Bai, T.; Murphy, V.; Strike, P.; Anders, R.F.; Batchelor, A.H. Refolding, purification, and crystallization of apical membrane antigen 1 from Plasmodium falciparum. Protein Expr. Purif. 2005, 41, 186–198, doi:10.1016/j.pep.2005.01.005.
[31]
Gapper, L.W.; Copestake, D.E.; Otter, D.E.; Indyk, H.E. Analysis of bovine immunoglobulin g in milk, colostrum and dietary supplements: A review. Anal. Bioanal. Chem. 2007, 389, 93–109, doi:10.1007/s00216-007-1391-z.
[32]
Every, A.L.; Ng, G.Z.; Skene, C.D.; Harbour, S.N.; Walduck, A.K.; McGuckin, M.A.; Sutton, P. Localized suppression of inflammation at sites of helicobacter pylori colonization. Infect. Immun. 2011, 79, 4186–4192, doi:10.1128/IAI.05602-11.
[33]
Chionh, Y.T.; Walduck, A.K.; Mitchell, H.M.; Sutton, P. A comparison of glycan expression and adhesion of mouse-adapted strains and clinical isolates of Helicobacter pylori. FEMS Immunol. Med. Microbiol. 2009, 57, 25–31, doi:10.1111/j.1574-695X.2009.00578.x.
[34]
Atkinson, S.C.; Dogovski, C.; Downton, M.T.; Pearce, F.G.; Reboul, C.F.; Buckle, A.M.; Gerrard, J.A.; Dobson, R.C.; Wagner, J.; Perugini, M.A. Crystal, solution and in silico structural studies of dihydrodipicolinate synthase from the common grapevine. PLoS One 2012, 7, e38318.
